These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12325105)

  • 1. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Califf RM
    Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial.
    Zwart-van Rijkom JE; van Hout BA
    Eur Heart J; 2001 Aug; 22(16):1476-84. PubMed ID: 11482921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 7. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical issues of platelet glycoprotein IIb/IIIa receptor inhibition: saving lives and saving money.
    Dippel EJ
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S28-34. PubMed ID: 12439434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
    Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
    Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.
    Admiral Investigators
    Eur Heart J; 2005 Dec; 26(23):2520-3. PubMed ID: 16249219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using cost-effectiveness for subsidy decisions.
    Glasziou P
    Heart; 1998 Jan; 79(1):7-8. PubMed ID: 9505908
    [No Abstract]   [Full Text] [Related]  

  • 13. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.
    Coller BS
    Thromb Haemost; 1997 Jul; 78(1):730-5. PubMed ID: 9198247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.
    Dobesh PP; Lanfear SL; Abu-Shanab JR; Lakamp JE; Gowda S; Haikal MY
    Ann Pharmacother; 2003 Oct; 37(10):1375-80. PubMed ID: 14519056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center.
    Zahn R; Fraiture B; Siegler KE; Schneider S; Gitt AK; Seidl K; Gandjour A; Wendland G; Vogt S; Lauterbach KW; Senges J
    Z Kardiol; 2003 Jun; 92(6):438-44. PubMed ID: 12819992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.